Merck Vaccine Approval Doesn't Quite Close Fair Value Gap
Merck's (MRK) stock has gained significant momentum in recent times, with a 90-day share price return of 16.08% and a one-year total shareholder return of 69.70%. The pharmaceutical company recently received European Commission marketing authorization for NOBIVAC NXT HCPChFeLV, a combination feline vaccine that uses RNA particle technology to target five significant feline pathogens.
The stock currently trades at $130.20, which is slightly below the widely followed fair value estimate of $132.78. However, Merck's acquisition and licensing strategy has nearly tripled its late-phase pipeline since 2021, with a potential commercial opportunity of over $50 billion by the mid-2030s.
An analyst narrative anchors Merck around a fair value of $132.78, but Simply Wall St's DCF model suggests a future cash flow value closer to $228.37, indicating that the stock is significantly undervalued. This disparity in valuation views highlights the complexities and uncertainties surrounding the company's prospects.
Merck's story can shift quickly if policy changes on drug pricing bite harder than expected or if the post-KEYTRUDA exclusivity period weighs more heavily on revenues. Investors should be aware of these key risks and carefully weigh them against the potential rewards when evaluating the stock.